Drug Profile


Alternative Names: LY-2189265; Trulicity

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics; Recombinant fusion proteins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 14 Aug 2017 Eli Lilly completes a phase II trial in Type-2 diabetes mellitus (Adjunctive treatment) in USA, Mexico, Czech Republic, Poland, Puerto Rico, Romania (SC) (NCT02973100)
  • 01 Feb 2017 Eli Lilly completes the phase III AWARD-10 trial in Type-2 diabetes mellitus in USA, Austria, Czech Republic, Germany, Hungary, Israel, Mexico, Puerto Rico and Spain (NCT02597049)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top